Innoviva Return on Investment 2006-2020 | INVA

Current and historical return on investment (ROI) values for Innoviva (INVA) over the last 10 years.
Innoviva ROI - Return on Investment Historical Data
Date TTM Net Income LT Investments & Debt Return on Investment
2020-03-31 $0.27B $0.79B 38.56%
2019-12-31 $0.25B $0.72B 37.83%
2019-09-30 $0.25B $0.67B 41.07%
2019-06-30 $0.25B $0.64B 48.53%
2019-03-31 $0.25B $0.59B 57.74%
2018-12-31 $0.24B $0.54B 67.42%
2018-09-30 $0.23B $0.27B 75.50%
2018-06-30 $0.21B $0.33B 65.12%
2018-03-31 $0.20B $0.27B 59.95%
2017-12-31 $0.18B $0.33B 52.40%
2017-09-30 $0.16B $0.36B 43.66%
2017-06-30 $0.14B $0.34B 40.37%
2017-03-31 $0.12B $0.37B 33.75%
2016-12-31 $0.11B $0.36B 30.58%
2016-09-30 $0.09B $0.35B 24.15%
2016-06-30 $0.07B $0.36B 17.89%
2016-03-31 $0.05B $0.37B 11.79%
2015-12-31 $0.03B $0.39B 7.18%
2015-09-30 $0.01B $0.42B 3.05%
2015-06-30 $-0.00B $0.44B -0.83%
2015-03-31 $-0.02B $0.47B -3.73%
2014-12-31 $-0.04B $0.50B -6.62%
2014-09-30 $-0.02B $0.51B -2.91%
2014-06-30 $-0.01B $0.55B -2.43%
2014-03-31 $-0.01B $0.55B -1.91%
2013-12-31 $-0.03B $0.59B -5.04%
2013-09-30 $-0.08B $0.62B -15.26%
2013-06-30 $-0.10B $0.55B -23.25%
2013-03-31 $-0.13B $0.55B -33.25%
2012-12-31 $-0.01B $0.33B -4.28%
2012-09-30 $-0.02B $0.35B -7.82%
2012-06-30 $-0.02B $0.36B -8.12%
2012-03-31 $-0.00B $0.18B -2.34%
2011-12-31 $-0.11B $0.09B -92.05%
2011-09-30 $-0.09B $0.11B -67.77%
2011-06-30 $-0.08B $0.14B -72.02%
2011-03-31 $-0.08B $0.15B -83.65%
2010-12-31 $-0.08B $0.15B -108.33%
2010-09-30 $-0.08B $0.03B -265.57%
2010-06-30 $-0.08B $0.05B -368.54%
2010-03-31 $-0.08B $0.06B -610.91%
2009-12-31 $-0.08B $-0.02B -1350.00%
2009-09-30 $-0.08B $-0.00B -384.62%
2009-06-30 $-0.08B $0.01B -234.38%
2009-03-31 $-0.08B $0.03B -184.09%
2008-12-31 $-0.09B $0.04B -162.45%
2008-09-30 $-0.11B $0.05B -358.40%
2008-06-30 $-0.13B $0.06B -1362.16%
2008-03-31 $-0.15B $0.08B 1507.69%
2007-12-31 $-0.17B $-0.07B 676.00%
2007-09-30 $-0.18B $-0.04B -2346.67%
2007-06-30 $-0.18B $-0.02B -441.21%
2007-03-31 $-0.18B $0.02B -233.99%
2006-12-31 $-0.18B $0.06B -161.63%
2006-09-30 $-0.18B $0.10B -165.83%
2006-06-30 $-0.18B $0.13B -162.53%
2006-03-31 $-0.17B $0.16B -148.67%
2005-12-31 $-0.15B $0.06B -130.42%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.408B $0.261B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.076B 16.59
Roche Holding AG (RHHBY) Switzerland $294.143B 0.00
Merck (MRK) United States $207.633B 15.04
Pfizer (PFE) United States $199.918B 12.41
Novartis AG (NVS) Switzerland $196.843B 15.36
Novo Nordisk (NVO) Denmark $151.861B 25.29
Eli Lilly (LLY) United States $142.712B 23.10
AstraZeneca (AZN) United Kingdom $141.323B 29.11
Bristol-Myers Squibb (BMY) United States $138.771B 11.59
AbbVie (ABBV) United States $138.592B 10.18
Sanofi (SNY) $125.457B 14.52
GlaxoSmithKline (GSK) United Kingdom $104.605B 12.49
Bayer (BAYRY) Germany $69.270B 9.88
H Lundbeck (HLUYY) Denmark $8.181B 14.21